Search
Retifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigational[L45608,L45618] On March 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). … On October 2021, Incyte Biosciences withdrew its application for a marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal.
Glycopyrronium
go.drugbank.com/drugs/DB00986ApprovedInvestigationalVet approved[L33105] Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium]. … [A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090]
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigationalCentanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant. … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.
Ladarixin
go.drugbank.com/drugs/DB16212InvestigationalLadarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).
Categories: Receptors, Interleukin-8A, antagonists & inhibitorsVB10.16
go.drugbank.com/drugs/DB17512InvestigationalVB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. … It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting
Binodenoson
go.drugbank.com/drugs/DB04853InvestigationalBinodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor. … This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion
Mefloquine
go.drugbank.com/drugs/DB00358ApprovedIt was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. … Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world.
Synonyms: (DL-ERYTHRO-.ALPHA.-2-PIPERIDYL-2,8-BIS(TRIFLUOROMETHYL)-4-QUINOLINEMETHANOLOxytocin
go.drugbank.com/drugs/DB00107ApprovedInvestigationalVet approved[A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work. … [A229013] Oxytocin also serves a role in metabolic homeostasis and cardiovascular regulation.[A228593,A229098]
Vardenafil
go.drugbank.com/drugs/DB00862Approved[A258318] The FDA approved the use of vardenafil for the treatment of erectile dysfunction in 2003. … [A258313] The use of vardenafil as a monotherapy for the treatment of pulmonary arterial hypertension has also been evaluated.[A258308]
Products: Vardenafil 1 A Pharma 5 mg - Filmtabletten, Vardenafil 1 A Pharma 10 mg - FilmtablettenPexidartinib
go.drugbank.com/drugs/DB12978ApprovedInvestigational[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. … [L7901] While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index